Professor Jonathan Ledermann
University College London Hospital, NW1 2BU
JAVELIN OVARIAN 100
Clinical trial locations
Please note that recruitment for this trial is now closed.
This is a phase III trial looking at the efficacy and safety of a drug called avelumab in combination with and / or following carboplatin and paclitaxel based chemotherapy. It is for women who have just been diagnosed with ovarian cancer who haven't started treatment.
About the trial
This trial is looking at whether the additional drug treatment of avelumab alongside platinum based chemotherapy improves progression free survival (the length of time during and after treatment that a woman lives with the disease but it does not get worse) in women with stage III / IV disease at diagnosis.
It is a three arm trial:
- Carboplatin and paclitaxel – three weekly (with the option of weekly paclitaxel)
- Carboplatin and paclitaxel – followed by avelumab two weekly
- Carboplatin and paclitaxel – three weekly (with the option of weekly paclitaxel) with avelumab three weekly during treatment followed by two weekly as maintenance
Who can take part?
Women who are recently diagnosed with epithilial ovarian cancer and have not yet received any treatment.